Unmet Needs in the Management of Patients with Hyperlipidemia

Now Viewing

EP: 1.Unmet Needs in the Management of Patients with Hyperlipidemia

EP: 2.Target LDL-C Levels for Patients

EP: 3.Guideline Recommendations for LDL-C Management

EP: 4.Weighing the Benefits and Risks of Statin Therapy

EP: 5.Important Treatment Considerations With LDL-C– Lowering Therapies

EP: 6.Effective Approaches for Utilizing Nonstatin Therapies

EP: 7.Mechanisms of Action of Nonstatin Therapies

EP: 8.Cost and Safety of Novel, Nonstatin Therapies

EP: 9.Clinical Value of Nonstatin Therapies

EP: 10.Deciding Between Novel, Nonstatin Therapies

EP: 11.Optimizing Treatment of Patients on LDL-C–Lowering Therapies

EP: 12.Identifying Nonadherence in Patients With Hyperlipidemia

EP: 13.Patient Education for LDL-C–Lowering Therapies

EP: 14.Monitoring Patients for Adverse Events and Optimizing Access to Therapies

EP: 15.Additional Considerations for LDL-C–Lowering Therapies

EP: 16.Future Considerations for the Management of Hyperlipidemia

Video content above is prompted by the following:

• In your clinical experience, how frequently does maximally tolerated statin therapy fail to lower low-density lipoprotein cholesterol levels below 70 mg/dL in high-risk patients with atherosclerotic cardiovascular disease?
• How about levels below 55 mg/dL?
• Patient adherence to statins is often suboptimal. What are your best methods to optimize adherence?
• In which scenarios do you switch patients’ therapies to optimize adherence?